Study finds potential type 2 diabetes aid in Takeda's drug

06/29/2011 | San Francisco Chronicle

A study presented at the annual meeting of the American Diabetes Association found that Takeda Pharmaceutical's TAK-875 drug fared better in reducing the risk of hypoglycemia in patients with type 2 diabetes compared to those in glimepiride and placebo treatments. It was just as effective as glimepiride in lowering hemoglobin A1c.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC